Adaptive Biotechnologies Corporation — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Figures are unaudited and in millions of dollars except per-share data, percentages, and test volumes. The company develops immune-medicine and minimal residual disease (MRD) products and services, including clonoSEQ and immunoSEQ.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $48.9 | $43.7 | $86.6 | $82.3 |
| Gross profit / gross margin | $31.0 / 63% | $30.4 / 70% | $50.0 / 58% | $55.9 / 68% |
| Operating loss | $(47.8) | $(52.5) | $(105.0) | $(115.6) |
| Net loss attributable to Adaptive | $(47.8) | $(52.0) | $(105.5) | $(114.8) |
| Net loss per share | $(0.33) | $(0.37) | $(0.73) | $(0.81) |
| Adjusted EBITDA (non-GAAP) | $(24.8) | $(33.1) | $(61.9) | $(76.2) |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $(82.7) | $(111.5) |
- Revenue mix: Q2 Immune Medicine revenue was $23.0 million, up 3%; MRD revenue was $25.9 million, up 22%. For the first half, Immune Medicine revenue fell 9% to $39.3 million, while MRD revenue rose 21% to $47.3 million.
- Growth and volume: clonoSEQ reports delivered increased 52% to 13,665 in Q2 and 56% to 25,744 for the first half. Q2 revenue growth also reflected a $7.7 million Genentech regulatory milestone recognized in Immune Medicine collaboration revenue.
- Margins and costs: Gross margin declined year over year in both periods as cost of revenue grew faster than revenue. The company cited greater production-lab usage, laboratory-consolidation overhead, and higher sample volume. Research and development expense declined, primarily due to lower investment in T-Detect, the TCR-Antigen Map, and drug discovery.
- Cash and liquidity: Cash, cash equivalents, and marketable securities totaled $417.2 million at June 30, 2023, versus $498.2 million at December 31, 2022. Six-month operating cash use was $82.7 million; investing activities provided $100.3 million, primarily from marketable-security maturities. Management expects existing liquidity to fund operating expenses and capital needs for at least the next 12 months.
- Debt-like obligations: The revenue interest liability was $128.2 million, up from $125.4 million at year-end. The related Purchase Agreement carries an estimated effective interest rate of 11.4%; interest expense was $3.6 million in Q2 and $7.1 million in the first half. Operating lease liabilities totaled $103.5 million, including current and long-term amounts.
Material changes, outlook, and risks
- Q2 revenue increased 12%; first-half revenue increased 5%. Improved clinical clonoSEQ and MRD testing revenue was partly offset by lower Immune Medicine service revenue and fewer regulatory milestone revenues than in the first half of 2022.
- Management expects revenue to grow over the long term, while noting near-term variability from customer sample delivery, milestone timing, project decisions, and changes in estimates. No specific revenue, earnings, or cash-flow guidance is provided in the supplied filing text.
- The company deferred further T-Detect commercialization until it has stronger evidence across disease states and a clearer reimbursement path. It expects short-term decreases in R&D, sales and marketing, and general and administrative expenses; laboratory consolidation and other near-term investments may affect cost of revenue.
- Genentech collaboration payments depend on development, regulatory, and commercial milestones. The company reported up to $399.5 million of potential future MRD milestone payments if customers’ therapeutics obtain specified regulatory approvals; these are contingent and not assured.
- Key risks include persistent operating losses and cash burn, execution and market acceptance of products, reimbursement and testing utilization, reliance on collaborators and third parties, milestone uncertainty, supplier concentration, and interest-rate exposure. The filing says there were no material changes to previously disclosed risk factors and no material legal proceedings as of June 30, 2023.
- The company reported effective disclosure controls and procedures and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clonoSEQ test-volume growth translates into sustained revenue growth and improved gross margins.
- How cash burn compares with management’s stated minimum 12-month liquidity runway, including future working-capital and laboratory-consolidation needs.
- The assumptions and future cash-payment burden of the revenue interest Purchase Agreement, including any additional funding installments and revenue-based payments.
- Progress, timing, and probability of Genentech and other customer milestones, and the effects of collaboration spending and revenue-recognition estimates.
- Whether lower R&D investment reflects planned prioritization and how it affects product development, T-Detect, and the TCR-Antigen Map.